Image

Paramedical Tele-education on Moderate Depressive Episodes

Paramedical Tele-education on Moderate Depressive Episodes

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Considering that one out of five people may experience depression during the course of their life, and that compliance to anti-depression medication is often not optimal.

Psycho-educational interventions are recommended in international clinical practice guidelines for the management of depression. They are the first step in the treatment protocol.

Psychoeducation in the treatment of depressive episodes has been shown to be an effective intervention because it reduces depressive symptoms, the risk of relapse or recurrence and improves adherence to treatment.

In France, there are only one approved psycho-education programme, but it concerns a population of patients under psychiatric care.

No psycho-education programme has yet been carried out or evaluated in France on depressed patients followed up in primary care by their General Practitioner.

Recent changes in our healthcare practices, which have required adaptation to the pandemic context, have led to the development of the use of telemedicine.

This study aims to evaluate a new and 100% remote educational program adapted to patients ongoing moderate depression and focused on medication adherence, economic gain and patients and professional satisfaction.

Description

In addition to the usual standard care, recruited patients will benefit from either an individual tele-education programme or standard care following the randomisation.

The psycho-education programme is based on 3 dimensions: educational (nature of the information and how it should be delivered), psychological (revelation of the diagnosis and transmission of information in a personalised way), behavioural and cognitive (restoring the skills and mobilising the resources of the subject in their daily functioning and in their relationship with the disease (management of treatment and communication skills in particular).

A low number of sessions has been chosen, as it is more appropriate for this population, whose disorders are not severe and who do not require specialist care. The emphasis was placed on personalising the information, with one-to-one sessions.

The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks.

The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment, in order to personalise the information to be provided about the programme.

The second session will focus on personalised hygienic and dietary measures. This will involve identifying sleep habits and leisure activities through behavioural analysis, and then identifying coping strategies with the patient in order to identify habits that can help combat depression.

A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed.

A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment.

The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent.

The liaison note is drawn up by the nurse with the patient for the general practitioner, focusing on: the patient's resources, in particular a personalised activity programme, and the patient's entourage, the areas of weakness identified and the risks identified of discontinuity in compliance.

Patients in the control group will receive standard care as usual. An educational booklet on depression, produced by the Institut National de Prévention et d'Education pour la Santé, will be sent to them by email after randomisation. It covers the symptoms, treatments and professionals to be consulted about depression. Patients will be able to consult this guide whenever they wish, without restriction, throughout the study.

Patients will usually be monitored by their General Practioner (GP), who may contact and refer them to the DSPP for psychiatric advice at any time during the study. The GP remains the referent for the patient's mental health care, with the support of the DSPP.

All participants in the study (control and experimental groups) may also be monitored by a psychologist, and will complete questionnaires.

Eligibility

Inclusion Criteria:

  • Presenting a depressive episode of moderate intensity according to the Diagnostic and Statistical Manual (DSM)-V
  • With a prescription for an antidepressant started less than 2 months before inclusion in the trial.
  • Whose state of health is compatible with follow-up by their GP (possibility of occasional advice from a psychiatrist).
  • Have Internet access at home (computer) and are able to use the digital platform.

Exclusion Criteria:

  • Patients who are unable to complete self-questionnaires (language barrier, etc.)
  • Who have already undergone a psycho-education or therapeutic patient education programme regarding depression.
  • Whose state of health requires follow-up by a psychiatrist

Study details
    Depression
    Depression Moderate

NCT06014125

University Hospital, Toulouse

18 February 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.